Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CURIS INCCRIS · Entity 8401 | Head of Research & Development | January 20, 2023 | January 24, 2023 |
| Indaptus Therapeutics, Inc.INDP · Entity 6530 | Director | June 10, 2025 | June 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CURIS INC
Report date January 20, 2023 · Filed January 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2033-01-19 | Direct | 350,000 |
Reported balance
After 2023-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-20 · Grant · Acquired 350,000 · Balance 350,000 F1: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 20, 2024 and as to an additional 6.25% of the original shares each successive quarter and until January 20, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 20, 2024 and as to an additional 6.25% of the original shares each successive quarter and until January 20, 2027.
Indaptus Therapeutics, Inc.
Report date June 10, 2025 · Filed June 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2035-06-10 | Direct | 12,500 |
Reported balance
After 2025-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 12,500 · Balance 12,500 F1: The stock option vests and becomes exercisable on June 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable on June 10, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2025 Filed Jun 11, 2025 16:05 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001641172-25-014694 · ownership.xml · derivative · entry 1 Martell Robert · CIK 0001529922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2035-06-10 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2026. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 17:00 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001493152-24-023150 · ownership.xml · derivative · entry 1 Martell Robert · CIK 0001529922 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-06-06 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on June 6, 2025. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 17:58 UTC | Indaptus Therapeutics, Inc. INDP · Entity 6530 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0001493152-23-005058 · ownership.xml · derivative · entry 1 Martell Robert · CIK 0001529922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-02-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable on February 13, 2024. Read SEC document |
| January 20, 2023 Filed Jan 24, 2023 21:09 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 350,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001108205-23-000010 · wf-form4_167459436111911.xml · derivative · entry 1 Martell Robert · CIK 0001529922 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2033-01-19 F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 20, 2024 and as to an additional 6.25% of the original shares each successive quarter and until January 20, 2027. Read SEC document |
| January 29, 2022 Filed Jan 31, 2022 22:16 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 252,000 | $0.00 Strike: $3.09 | $0.00 |
DisclosureSEC source: 0001209191-22-005660 · doc4.xml · derivative · entry 1 Martell Robert · CIK 0001529922 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,000 Underlying: Common stock · 252,000 shares Expires 2032-01-28 F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 29, 2023 and as to an additional 6.25% of the original shares each successive quarter and until January 29, 2026. Read SEC document |
| January 28, 2021 Filed Jan 29, 2021 21:30 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 126,000 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001209191-21-006101 · doc4.xml · derivative · entry 1 Martell Robert · CIK 0001529922 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,000 Underlying: Common stock · 126,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on January 28, 2022 and as to an additional 6.25% of the original shares each successive quarter and until January 28, 2025. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:07 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 385,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001209191-20-016237 · doc4.xml · derivative · entry 1 Martell Robert · CIK 0001529922 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,000 Underlying: Common stock · 385,000 shares Expires 2030-03-01 F1 · derivative.exercise_date: The option grant described in this Form 4 filing vests as to 25% of the original shares on March 2, 2021 and as to an additional 6.25% of the original shares each successive quarter and until March 2, 2024. Read SEC document |
| May 23, 2019 Filed May 28, 2019 20:13 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 386,996 | $0.00 Strike: $1.16 | $0.00 |
DisclosureSEC source: 0001209191-19-032970 · doc4.xml · derivative · entry 1 Martell Robert · CIK 0001529922 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,996 Underlying: Common stock · 386,996 shares Expires 2029-01-20 F1 · date: This option grant, as disclosed in Curis Inc.'s 2019 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 21, 2019, contingent upon shareholder approval of an amendment to Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the amendment to the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 23, 2019, at the 2019 annual meeting of shareholders, Curis's shareholders approved the amendment to the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 21, 2020 and as to an additional 6.25% of the original shares each successive quarter and until January 21, 2023. F1 · derivative.exercise_date: This option grant, as disclosed in Curis Inc.'s 2019 proxy statement, was approved by the Compensation Committee of the Board of Directors of Curis, Inc. on January 21, 2019, contingent upon shareholder approval of an amendment to Curis's Third Amended and Restated 2010 Stock Incentive Plan to increase the number of shares authorized for issuance thereunder; and further provided that such option would not be exercisable and no common stock would be issued thereunder, if the amendment to the Third Amended and Restated 2010 Plan was not approved by Curis's shareholders. On May 23, 2019, at the 2019 annual meeting of shareholders, Curis's shareholders approved the amendment to the Third Amended and Restated 2010 Plan. The option grant described in this Form 4 filing vests as to 25% of the original shares on January 21, 2020 and as to an additional 6.25% of the original shares each successive quarter and until January 21, 2023. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:40 UTC | CURIS INC CRIS · Entity 8401 | SaleCommon Stock | 5,500 | $1.07 | $5,900.40 |
DisclosureSEC source: 0001209191-19-005355 · doc4.xml · nonDerivative · entry 2 Martell Robert · CIK 0001529922 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,027 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan to cover tax obligations. F4 · price: The price reported in Column 4 is a weighted average price for the shares sold. These shares were sold in multiple transactions at prices ranging from $1.02 to $1.09, inclusive. The reporting person undertakes to provide to Curis, Inc., any security holder of Curis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth on this Form 4. F2 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 21:40 UTC | CURIS INC CRIS · Entity 8401 | Tax withholdingCommon Stock | 8,473 | $1.07 | $9,066.11 |
DisclosureSEC source: 0001209191-19-005355 · doc4.xml · nonDerivative · entry 1 Martell Robert · CIK 0001529922 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,527 F1 · kind: Shares were withheld by the Company to satisfy minimum statutory withholding requirements related to a vesting of a service-based restricted stock award granted on January 22, 2018. F2 · balance_after: On May 29, 2018, the Company effected a 1-for-5 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 20:03 UTC | CURIS INC CRIS · Entity 8401 | GrantEmployee stock option (right to buy) · Derivative | 303,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001209191-18-035586 · doc4.xml · derivative · entry 1 Martell Robert · CIK 0001529922 · Head of Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 303,000 Underlying: Common stock · 303,000 shares Expires 2028-05-31 F1 · derivative.exercise_date: This option vests as to 25% of the original shares on June 1, 2019 and as to an additional 6.25% of the original shares underlying the award each successive three month period through and until June 1, 2022, subject to continued service. Read SEC document |
| January 22, 2018 Filed Jan 24, 2018 22:02 UTC | CURIS INC CRIS · Entity 8401 | GrantCommon stock | 185,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005165 · doc4.xml · nonDerivative · entry 1 Martell Robert · CIK 0001529922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 F1 · shares: This award is in the form of restricted common stock. The award vests as to 100% of the underlying shares on the first anniversary of the date of grant. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:58 UTC | CURIS INC CRIS · Entity 8401 | GrantNon-qualified stock option · Derivative | 120,000 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001209191-17-016752 · doc4.xml · derivative · entry 1 Martell Robert · CIK 0001529922 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-02-27 F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and 1/12th of the total shares will vest monthly beginning on January 1, 2017 until all of the shares underlying the award become vested on January 1, 2018, subject to the director's continued service with the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.